What changed today in Metabolic: 1 trial update
Every new official record on the Metabolic & Weight-Loss Intelligence desk since this morning, each linked to its primary source.
Automated from official records1 source1 min read
Liraglutide
Liraglutide is a GLP-1 receptor agonist marketed under brand names including Victoza and Saxenda.
Emerging
- Editorial attention
- Emerging
- Tracked this week
- 0
- Sources this week
- 0
- Last activity
- Nov 2, 2026
Signal strength reflects editorial attention across tracked sources — not medical certainty or strength of evidence.
- Pending editorial review
A system check is an automated check of the official sources, not a human review. An editorial review is recorded only when one of our editors has reviewed the page.
Liraglutide at a glance
- About this topic
- Liraglutide is a GLP-1 receptor agonist marketed under brand names including Victoza and Saxenda.
- Current status
- No editor-reviewed status summary yet. The official records below update automatically.
- Last updated
- Primary sources
- Latest official record: New trial registered: The Effect of Liraglutide on Body Weight, Body Composition, Ectopic Lipid Accumulation and Insulin Sensitivity in Subjects With Overweight or… (opens the source in a new tab) (ClinicalTrials.gov (U.S. National Library of Medicine), Nov 2, 2026)
- Key facts from tracked records
- 37 clinical trials tracked from ClinicalTrials.gov
- 3 NPHLA briefings on this topic
What’s the latest on Liraglutide?
3 totalWhat changed today in Metabolic: 6 trial updates
Every new official record on the Metabolic & Weight-Loss Intelligence desk since this morning, each linked to its primary source.
Automated from official records9 sources1 min read
What changed today in Metabolic: 5 trial updates, 2 drug-shortage updates, 1 new study
Every new official record on the Metabolic & Weight-Loss Intelligence desk since this morning, each linked to its primary source.
Automated from official records9 sources1 min read
What do the official records show?
Primary sources and peer-reviewed research- New trial registered: The Effect of Liraglutide on Body Weight, Body Composition, Ectopic Lipid Accumulation and Insulin Sensitivity in Subjects With Overweight or… (opens the source in a new tab)
Phase 4, Medical University of Bialystok. Conditions: Obesity & Overweight. Interventions: liraglutide; Low-calorie diet with dietician's monitoring. Investigational: trial-stage therapies are not approved for the use studied.
- Results posted on ClinicalTrials.gov: A Study to Evaluate the Effect of Genetic Variation on Beta-cell Function During Fasting and Hyperglycemia in Nondiabetics (opens the source in a new tab)
Phase 3, Adrian Vella. Conditions: Healthy. Interventions: Saline; Exendin-9,39; Liraglutide. Investigational: trial-stage therapies are not approved for the use studied.
- Drug shortage update: Liraglutide Injection — Current (opens the source in a new tab)
Liraglutide, Injection, 6 mg/1 mL (NDC 0143-9144-02). Company: Hikma Pharmaceuticals USA, Inc.
- Drug shortage update: Liraglutide Injection — Current (opens the source in a new tab)
Liraglutide, Injection, 6 mg/1 mL (NDC 0143-9144-03). Company: Hikma Pharmaceuticals USA, Inc.
- Drug shortage update: Liraglutide Injection — Current (opens the source in a new tab)
Victoza, Injection, 6 mg/1 mL (NDC 0169-4060-13). Company: Novo Nordisk, Inc.. Estimated shortage duration: TBD
- Drug shortage update: Liraglutide Injection — Current (opens the source in a new tab)
Victoza, Injection, 6 mg/1 mL (NDC 0169-4060-12). Company: Novo Nordisk, Inc.. Estimated shortage duration: TBD
- Drug shortage update: Liraglutide Injection — Current (opens the source in a new tab)
Liraglutide, Injection, 6 mg/1 mL (NDC 0480-3667-22). Company: Novo Nordisk, Inc.. Distributed by Teva
- Drug shortage update: Liraglutide Injection — Current (opens the source in a new tab)
Saxenda, Injection, 6 mg/1 mL (NDC 0169-2800-15). Company: Novo Nordisk, Inc.. Product will be available until discontinuation in January 2027
Which clinical trials are being tracked?
All trials- GLP-1 Receptor Agonists in the Surgical Patient: Prevalence, Epidemiology, and Pulmonary Complications
University of Virginia. Conditions: GLP-1 Receptor Agonist Treatment. Investigational — not approved for the use studied.
- CLEAR-GLP1: 24-hour Clear Liquid Diet vs. Standard Fasting for Upper Gastrointestinal Endoscopy in Patients Taking Agonists of the GLP-1 Receptor
Portuguese Oncology Institute, Coimbra. Conditions: Retained Gastric Content; Delayed Gastric Emptying; Obesity; Type 2 Diabetes Mellitus (DM). Investigational — not approved for the use studied.
- Preoperative Weight Loss for Open Abdominal Wall Reconstruction
Benjamin T. Miller. Conditions: Abdominal Wall Hernia. Investigational — not approved for the use studied.
- GLP-BARI-VAN: Two-Year Weight Loss With GLP-1 Medications Compared With Sleeve Gastrectomy in Adults With Obesity
Yuzuncu Yil University. Conditions: Obesity & Overweight. Investigational — not approved for the use studied.
- The Effect of Liraglutide on Body Weight, Body Composition, Ectopic Lipid Accumulation and Insulin Sensitivity in Subjects With Overweight or Obesity Without Diabetes
Medical University of Bialystok. Conditions: Obesity & Overweight. Investigational — not approved for the use studied.
- Changes in Body Composition Following Pharmacological Treatment for Obesity.
Hospital San Carlos, Madrid. Conditions: Obesity (BMI Equal to or >30); Weight Regain After Bariatric Surgery. Investigational — not approved for the use studied.